FFAR4 and polycystic ovary syndrome: Compared with the PCOS-IR group, the PCOS-IR+GPR120 agonist, PCOS-IR+LrB (40 mg/kg), and PCOS-IR+LrB (20 mg/kg) groups presented significant increases in the expression levels of LKB1 and AMPK in ovarian tissues (Figure 12A,D), whereas the PCOS-IR+LrB (10 mg/kg) group presented significant increases in the expression of LKB1 and AMPK (Figure 12A,D).